참여 물질
| 역할 | 이름 | HCID | 투입량 |
|---|
| 반응물 | (R)-2-(5-methyl-1,2,4-oxadiazol-3-yl)but-3-yn-2-ol | HCID 86669593 | — |
| 반응물 | HCID 178422860 | HCID 178422860 | — |
| 생성물 | HCID 178422861 | HCID 178422861 | — |
반응 단계
10-bromo-9-fluoro-3-iodo-5,6-dihydrobenzo[f]imidazo[1,2-d][1,4]oxazepine-2-carboxamide was reacted with (2-tert-butoxycarbonyl-5-methyl-pyrazol-3-yl)boronic acid similarly to as described in Example 4 to produce crude 10-bromo-9-fluoro-3-(3-methyl-1H-pyrazol-5-yl)-5,6dihydrobenzo[f]imidazo[1,2-d][1,4]oxazepine-2-carboxamide. 10-bromo-9-fluoro-3-(3-methyl-1H-pyrazol-5-yl)-5,6dihydrobenzo[f]imidazo[1,2-d][1,4]oxazepine-2-carboxamide was reacted with (2R)-2-(5-methyl-1,2,4-oxadiazol-3-yl)but-3-yn-2-ol via General Procedure E to afford 5.8 mg (6.6%) 9-fluoro-10-[(3R)-3-hydroxy-3-(5-methyl-1,2,4-oxadiazol-3-yl)but-1-ynyl]-3-(3-methyl-1H-pyrazol-5-yl)-5,6-dihydroimidazo[1,2-d][1,4]benzoxazepine-2-carboxamide following reverse phase purification. M+1=478.
출처 및 근거
| DOI | 10.6084/m9.figshare.5104873.v1 |
|---|
| 특허 번호 | US09034866B2 |
|---|
| 출처 데이터셋 | uspto-grants-2015_05 |
|---|
| ORD ID | ord-218afa56868b4151b112229c7f1bfec6 |
|---|
| 출처 메모 | uspto-grants-2015_05 |
|---|